Search

Displaying results 491 - 500 of 4627 in total
  1. Drug

    Barium sulfate

    go.drugbank.com/drugs/DB11150
    Approved

    Therapeutic advantages of barium sulfate in diagnostic procedures include both its low water solubility and high level of clearance from the body [FDA label]. … Barium sulfate is ingested by mouth or administered rectally and combined with granules of effervescent bicarbonate to enhance distension of the GI tract, allowing for enhanced gastrointestinal tract visualization

  2. Drug

    Quetiapine

    go.drugbank.com/drugs/DB01224
    ApprovedInvestigational

    Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. … [L8546] Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment.

  3. Drug

    Tazobactam

    go.drugbank.com/drugs/DB01606
    ApprovedInvestigational

    Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.

  4. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    [L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination … therapy developed by Mayne Pharma in 1992.

  5. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    [L11761] Inotersen has been shown to improve the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis [A39493]. … Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.

  6. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    It displayed high affinity (0.53–1.53 nmol/L) to apixaban, betrixaban, edoxaban and rivaroxaban [A35518]. … Andexanet alfa retains the structural similarity to that of endogenous human factor Xa, but exists in its mature functional form without the need for activation via the intrinsic or extrinsic coagulation

  7. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    Segesterone acetate is not an orally active compound, but it is proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel [A37090]. … The introduction of this new contraceptive method offers an expansion of birth control options for women while maintaining high efficacy and acceptability similar to existing shorter-acting combined hormonal

  8. Drug

    Aztreonam

    go.drugbank.com/drugs/DB00355
    ApprovedInvestigational

    A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinf...

  9. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.

  10. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.